<b>Background and Aims</b>: Prostate specific membrane antigen (PSMA) is specifically expressed on prostate epithelial cells and markedly overexpressed in almost all prostate cancers.
<b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels.
<b>Conclusion:</b> PSMA-targeting probes with trifluoroborate prosthetic groups represent promising candidates for prostate cancer imaging because of facile labeling while affording high tumor uptake values and contrast ratios that are similar to those obtained with <sup>18</sup>F-DCFPyL.
<b>Conclusion:</b> In our analysis, preoperative 1-stop-shop <sup>68</sup>Ga-PSMA-11 PET/MRI performs at least equally for T and N stage prediction compared with nomograms in high-risk prostate cancer patients.
<b>Conclusion:</b> In this pilot study, <sup>18</sup>F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
<b>Conclusion:</b> Synchronous <sup>68</sup>Ga-labeled prostate-specific membrane antigen-avid malignancies were rare (0.7%) in PC patients; atypical lesions were more commonly unusual PC metastases (1.0%) or benign (3.1%).
<b>Conclusion:</b> The radiofluorinated PSMA ligand showed promising characteristics in its preclinical evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies.
<b>Conclusion:</b> This case series suggests improved detection rates for <sup>68</sup>Ga-PSMA-11 PET/CT when compared with <sup>18</sup>F-fluciclovine PET/CT in patients with recurrent PCa.
<b>Conclusion:</b><sup>177</sup>Lu-PSMA-617 (120 MBq) and high specific activity resulted in the highest efficacy in a syngeneic model of murine prostate cancer.
<b>Introduction:</b><sup>68</sup>Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as <sup>68</sup>Ga-PSMA-11, are promising small molecules for targeting prostate cancer (PCa).
<b>Methods:</b> In an Institutional Review Board-approved pilot study, initial clinical utility of PET/CT imaging with <sup>18</sup>F-JK-PSMA-7 was directly compared to <sup>68</sup>Ga-PSMA-11 PET/CT in a group of 10 patients with prostate cancer.
<b>Methods:</b> Mouse xenograft models of LNCaP (PSMA-positive prostate cancer) (<i>n</i> = 18) were prepared and divided into 3 groups according to the peptide concentration injected: a high-MA group (1,013 ± 146 GBq/μmol; <i>n</i> = 6), a medium-MA group (100.7 ± 23.1 GBq/μmol; <i>n</i> = 6), and a low-MA group (10.80 ± 2.84 GBq/μmol; <i>n</i> = 6).
<b>Methods:</b> Murine prostate cancer RM1 sublines (ras myc transformed cells of C57BL/6 prostate origin) expressing varying levels of human PSMA were injected into the shoulder of C57BL/6 mice on day 0.
<b>Methods:</b> Serial <sup>68</sup>Ga-PSMA-11 PET was prospectively performed at baseline and on days 9, 18, and 28 in 8 men with measurable metastatic hormone-sensitive PCa commencing LHRH ± bicalutamide (cohort 1) and 7 men with castrate-resistant PCa commencing either enzalutamide or abiraterone (cohort 2).
<b>Methods:</b> Six patients (aged 62-68 y; mean, 66 ± 2 y) with suspected prostate cancer recurrence after previous treatment were administered 2 MBq of <sup>18</sup>F-PSMA-11 per kilogram of body weight and then underwent low-dose PET/CT imaging at 0, 20, 50, 90, and 300 min after injection.
<b>Methods:</b><sup>68</sup>Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (<i>n</i> = 25), primary diagnosis (<i>n</i> = 10), biochemical persistence after primary therapy (<i>n</i> = 5), or staging of known metastatic disease (<i>n</i> = 10).
<b>Objectives:</b> Lutetium-177 (<sup>177</sup>Lu)-PSMA-617 (LuPSMA) is a radioligand with high affinity for prostate specific membrane antigen (PSMA) enabling targeted beta-irradiation of prostate cancer.
<b>Patients and methods:</b> Patients with prostate cancer (PCa) who underwent [<sup>68</sup>Ga]-PSMA-11 PET/CT followed by radical prostatectomy and pelvic lymph node dissection were prospectively enrolled (n=20).
<b>Results:</b> A total of 46 lesions in 22 patients were considered indeterminate for PCa (i.e., PSMA-RADS-3A [32 lesions] or PSMA-RADS-3B [14 lesions]) and were evaluable on follow-up imaging.